CTDH News and Press, Ctd Holdings Inc From 12/10/19

ORLANDO, Fla / ACCESSWIRE / December 10, 2019 / Sharon H. Hrynkow, Ph.D., Chief Scientific Officer of Cyclo Therapeutics (OTCQB: CTDH), was appointed to the President's Council of Advisors on Science and Technology (PCAST) in October. Dr. Hrynkow, a neuroscientist by training, has served in...

The Clinical Trial Mallinckrodt ( MNK ) is a small-cap ($245M) commercial-stage global specialty pharmaceutical company developing innovative therapeutics for diseases including autoimmune and rare diseases. Through several acquisition s and in-house research, MNK has developed a div...

Pivotal trial will study the intravenous administration of the Company’s Trappsol® Cyclo™ drug and will focus on systemic and neurologic outcomes Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products fo...

Publication describes favorable safety profile and efficacy in neurologic and other disease features in individual NPC patients following intravenous administration of drug Cyclo Therapeutics, Inc, (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based pro...

Trial Will Evaluate Safety and Efficacy of the Company’s Trappsol ® Cyclo™ Drug in Alzheimer’s Disease Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Dis...

ORLANDO, FL / ACCESSWIRE / October 28, 2019 / Cyclo Therapeutics (OTCQB:CTDH), formerly CTD Holdings, is moving forward on the development of an Alzheimer's treatment using its proprietary Trappsol® Cyclo™ after reporting successful results from its first year of dosing of the dr...

White House Announcement made on October 22, 2019 Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of diseases with unmet medical need, including Niemann-Pick Disease Type C and Alzheimer’s D...

Top line results are expected to be available in February 2020 Cyclo Therapeutics, Inc. (OTCQB: CTDH), formerly CTD Holdings, Inc., a biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that it has completed patient enrollment in ...

Announcement Made in Conjunction With October 19 th Global Awareness Day for Niemann-Pick Disease Sponsored by International Niemann Pick Disease Alliance Cyclo Therapeutics, Inc. (OTCQB:CTDH), formerly CTD Holdings, Inc., a biotechnology company that develops cyclodextrin-based product...

Reena Sharma, MD will serve as EU Coordinating Investigator for Extension Protocol Cyclo Therapeutics, Inc. (OTCQB: CTDH), formerly CTD Holdings, Inc., a biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced ...